Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550141 · ClinicalTrials.gov registry record · Phase 2
Emapalumab Prevention of CAR-T Cell Associated Toxicities
A Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT06550141: Recruiting Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, sponsored by Marcela V. Maus, M.D.,Ph.D..
NCT06550141 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 28 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550141, a Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Primary Outcome
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine Phosphate
- DRUG Axicabtagene Ciloleucel
- DRUG Emapalumab
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
What NCT06550141 shows while recruiting
NCT06550141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (87% lower).
The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT06550141 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06550141 about?
NCT06550141 is a clinical study titled "Emapalumab Prevention of CAR-T Cell Associated Toxicities". This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepletin...
What is the current status of trial NCT06550141?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-09-18. Estimated completion is 2027-08-01.
What conditions does trial NCT06550141 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06550141?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine Phosphate (DRUG), Axicabtagene Ciloleucel (DRUG), Emapalumab (DRUG).
Who is sponsoring clinical trial NCT06550141?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550141 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06550141's enrollment target sits among peer trials
28 83rd of 114 higher than 32 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
-
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI